Deep Sequencing of Circulating Tumor DNA for Personalized Cancer Detection and Monitoring?
Ash Alizadeh, MD, PhD
Wednesday, October 22, 2014
Tweet
Transcript
Embed
Email
Bookmark
<<
<
>
>>
Tweet
Facebook
Email
Chapters
Introduction
Circulationg Tumor DNA
Properties of cell-free DNA
Reference Ranges for Plasma Constituents
Challenges in Analyzing ctDNA
CAncer Personalized Profiling by Deep-Sequencing (CAPP-Seq)
CAPP-Seq for ctDNA Monitoring
CAPP-Seq Workflow
FACTERA: Genomic Fusion Discovery
Sensitive and Specific Detection of Circulationg Tumor DNA
Strong Assocation Between ctDNA Concentration and Tumor Volume
Monitoring ctDNA in Metastatic NSCLC
Detection and monitoring of Resistance Mutations and Tumor Heterogeneity
CAPP-Seq Analysis in a Stage IIB NSCLC Subject Treated with Radiotherapy
CAPP-Seq Analysis in a Stage IIIB NSCLC Subject Treated with Chemoradiotherapy
CAPP-Seq Analysis in a Stage IB NSCLC Subject Treated with Surgery
Published NGS Methods for Detecting ctDNA
A Spectrum of Opportunities
Potential Applications of CAPP-Seq: Late Stage Disease
CAPP-Seq for Cancer Detection
ctDNA Biology and Early Detection
Assay Requirements for Cancer Screening
Exploring Potential Application to Cancer Screening
Pan-Cancer CAPP-Seq
Some 10-Year Predictions for ctDNA
Acknowledgements
No transcript for this webinar
Product Details
Contact Us